Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2008

View Archived Issues

Alefacept found ineffective in treatment of severe alopecia areata

FDA approves Cleviprex for hypertension when oral therapy is not feasible

Novel radioligand for glycine transporter-1 under development by GSK in humans

Positive phase II results from studies of RAGE antagonist PF-04494700 in Alzheimer's disease

Phase II results encourage phase III investigation of LY-2062430 in Alzheimer's disease

Ustekinumab improves nail psoriasis in phase III trial

Recombinant adenovirus serotype 35 vectors evaluated in vivo as smallpox vaccine candidates

No significant improvement in psoriasis lesions seen with PTH (1-34) in phase IIa study

Evotec initiates phase I clinical trial of VR1 antagonist under development with Pfizer

4SC acquires 8 oncology projects from Nycomed

Astellas launches Mycamine in the U.K.

Kowa acquires ProEthic Pharmaceuticals

Emiliem and NIH Sign CRADA for development of novel mTOR inhibitors

Veridex acquires Immunicon corporation assets

Amicus successfully completes end of phase II meeting with FDA for Amigal

Novel agents for glaucoma reported in patent literature

Expression Genetics completes USD 12 million series B financing

Discovery of new anti-HIV agents reported in recent patents

Top-line results of phase II boceprevir study shows high SVR rate in HCV

AstraZeneca patents novel PDE4 inhibitors for asthma

Schering-Plough updates recent activities

Diovan HCT and Exforge approved for first-line blood pressure treatment

YM BioSciences reports positive results from phase II study of nimotuzumab in mCRC

CPEX and Serenity collaborate on drug candidate for urology indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...